GlassScriptPhysician profile
Lewis M Milrod
NPI 1851317572
$4,715.66
in general payments reported to CMS, 2019-2025
30 companies · $957 in 2025
The $957 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $614 · 2021: $713 · 2022: $497 · 2023: $378 · 2024: $766 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,364.41 | 2019-2025 | Qelbree, Qelbree |
| Ucb, INC. | $869.36 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Tris Pharma INC | $565.39 | 2019-2025 | Onyda Xr |
| Corium, LLC | $381.65 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $173.43 | 2025 | Jornay Pm |
| Upsher-Smith Laboratories LLC | $151.12 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $144.18 | 2020-2024 | |
| Neos Therapeutics, LP | $131.72 | 2019-2021 | |
| Adlon Therapeutics L.P. | $99.19 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $87.19 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $80.25 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $71.62 | 2019-2020 | |
| Rhodes Pharmaceuticals L.P. | $68.30 | 2019 | |
| Neurelis, INC. | $66.26 | 2020-2021 | |
| Aprecia Pharmaceuticals, LLC | $61.03 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $58.87 | 2022 | |
| Harmony Biosciences LLC | $57.88 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.51 | 2019-2022 | |
| Greenwich Biosciences, INC. | $43.00 | 2019-2020 | |
| Biogen, INC. | $36.09 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $27.54 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.00 | 2021 | |
| Avion Pharmaceuticals | $14.78 | 2023 | Methylphenidate Hydrochloride |
| Owp Pharmaceuticals, INC. | $14.62 | 2025 | Subvenite |
| Livanova USA, INC. | $14.00 | 2022 | |
| Zogenix INC. | $13.61 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.15 | 2023 | Koselugo |
| Biohaven Pharmaceutical Holding Company LTD. | $12.94 | 2022 | |
| Metacel Pharmaceuticals LLC | $9.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Milrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.